Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?
Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.
Type 2 diabetes (T2D) remains a significant global health challenge, particularly in developing countries. The International Diabetes Management Practices Study (IDMPS) provides valuable real-world evidence on the management and outcomes of T2D over a 12-year period. This article summarizes key findings from the IDMPS, highlighting trends in glycaemic control, therapy use, and care practices.
When to Initiate Basal Insulin?
The IDMPS collected data from 66,088 individuals with T2D across 49 countries, involving 6099 physicians. The study spanned seven cross-sectional waves from 2005 to 2017, with each physician collecting data from ten consecutive patients during a two-week period.
Key Highlights
- Glycaemic Control:
The proportion of participants achieving HbA1c <7% decreased from 36% in 2005 to 30.1% in 2017. This decline underscores persistent challenges in achieving optimal glycaemic control.
- Therapy Use:
Over 80% of participants were on oral glucose-lowering drugs (OGLDs), with a notable decline in sulfonylurea use. Insulin use increased from 32.8% to 41.2%, with a slight reduction in the time to insulin initiation.
- Diabetes Education:
The proportion of participants receiving diabetes education rose from 59.0% to 78.3%, reflecting an increased emphasis on patient education and self-management.
- Monitoring:
The frequency of HbA1c measurements improved significantly, with 92.9% of participants having at least two measurements within 12 months by the final wave.
Conclusion
Despite advancements in diabetes management, glycaemic control in developing countries remains suboptimal. The IDMPS highlights the need for systemic changes and better organization of care to improve outcomes for individuals with T2D. Enhanced diabetes education, timely therapy adjustments, and regular monitoring are crucial for achieving better glycaemic control and reducing the burden of diabetes-related complications.
Clincal implications for General Practice
Healthcare providers play a pivotal role in managing T2D. The findings from the IDMPS emphasize the importance of:
By addressing these areas, healthcare providers can significantly improve the quality of care for patients with T2D, ultimately leading to better health outcomes.
This summary provides a concise overview of the IDMPS findings and their implications for healthcare providers. For more detailed information, refer to the original article by Aschner et al. in Diabetologia.
Pour accéder à cette page, vous devez vous connecter. Si vous n'avez pas de compte, vous pouvez en créer un ici.
Références
-
Aschner, P., et al. (2020). Persistent poor glycaemic control in patients with type 2 diabetes: International Diabetes Management Practices Study (IDMPS). Diabetologia, 63(4), 711-721.
Articles liés
Act early, think holistically for your patients with Type 2 diabetes at very high cardiovascular risk
People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.1 The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.2,3
Pooled analysis: Interventional and observational studies
A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.1
Les contenus accessibles par ce site sont destinés exclusivement aux Professionnels de Santé.
Les contenus accessibles par ce site sont destinés
exclusivement aux Professionnels de Santé.
Sanofi met a votre disposition, sur un portail unique dédié aux professionnels de santé, des contenus exclusifs comprenant des contenus scientifiques et des outils pour votre pratique quotidienne.